- Conditions
- Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
- Interventions
- PRAM9, Regular Insulin + Pramlintide, Regular Insulin
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,613
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- High Intensity Interval Exercise, Moderate Intensity Continuous Exercise, Control
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Type 1 Diabetes Mellitus, Sleep
- Interventions
- Not listed
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Teens.Connect
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 11 Years to 14 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin Aspart, Insulin Lispro
- Drug
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
- Drug
- Lead sponsor
- Diasome Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Bioelectrical Impedance Analysis, Total Body Dual-energy X-ray Absorptiometry, Blood draw
- Diagnostic Test
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Type 1 Diabetes
- Interventions
- FAMS-T1D, Digital resources for diabetes
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Salt Lake City, Utah
- Conditions
- Type 1 Diabetes
- Interventions
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Biological · Device
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Loma Linda, California • Austin, Texas
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Interventions
- YH001, Envafolimab, Doxorubicin
- Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Chicago, Illinois • New York, New York + 3 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
- Biological · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Diabetes Mellitus, Insulin-Dependent
- Interventions
- FreeStyle Navigator Continuous Glucose Monitoring System
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- L. johnsonii Probiotic, Placebo Capsule
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Type 1 Diabetes
- Interventions
- telemedicine
- Other
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- teplizumab 1 mg/mL
- Drug
- Lead sponsor
- Provention Bio, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more
- Conditions
- Healthy Participants
- Interventions
- AZD5004, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more
- Conditions
- Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
- Interventions
- Sitagliptin (Januvia)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- Sensor wear
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Escondido, California • Santa Barbara, California • Renton, Washington
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Next Generation Extended Wear Sensors
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Chula Vista, California • Escondido, California • Palo Alto, California + 15 more
- Conditions
- Diabetes type1
- Interventions
- AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
- Biological · Drug
- Lead sponsor
- Precigen Actobio T1D, LLC
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
- Conditions
- Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
- Interventions
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Escondido, California • Santa Barbara, California • Torrance, California + 10 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more